XORTX Therapeutics, Inc.

XORTX Therapeutics is a biotechnology company dedicated to developing innovative therapies for patients with progressive kidney disease.

[XORTX Therapeutics, Inc. @XORTXinc]

More than 557,000 Americans are on dialysis.

Xortx Therapeutics is pioneering new therapies for progressive kidney disease.

$XRTX #KidneyDisease #APDKD

[XORTX Therapeutics, Inc. @XORTXinc]

Total Medicare spending for all chronic kidney diseases surpassed $85 billion.

Xortx Therapeutics is pioneering new therapies for progressive kidney disease.

$XRTX #KidneyDisease #APDKD

[XORTX Therapeutics, Inc. @XORTXinc]

Chronic kidney disease accounted for 23.5% of all Medicare expenditures.

Xortx Therapeutics is pioneering new therapies for progressive kidney disease.

$XRTX #KidneyDisease #APDKD

[XORTX Therapeutics, Inc. @XORTXinc]

Kidney disease is one of the top 10 causes of death in the United States. Killing more people each year than breast or prostate cancer.

Xortx Therapeutics is pioneering new therapies for progressive kidney disease.

$XRTX #KidneyDisease #APDKD

[XORTX Therapeutics, Inc. @XORTXinc]

Kidney disease currently affects more than 1 in 7 Americans.

Xortx Therapeutics is pioneering new therapies for progressive kidney disease.

$XRTX #KidneyDisease #APDKD

[XORTX Therapeutics, Inc. @XORTXinc]

37 million Americans have kidney disease.

Xortx Therapeutics is pioneering new therapies for progressive kidney disease.

$XRTX #KidneyDisease #APDKD

[XORTX Therapeutics, Inc. @XORTXinc]

Xortx Therapeutics' is pleased to announce a research paper titled “Raising serum uric acid with a uricase inhibitor worsens PKD in rat and mouse models" has been accepted for publication in the peer-reviewed American Journal of Physiology-Renal Physiology and published online April 19, 2024.

$XRTX #ADPKD

https://t.co/YmiEDreNCs

[XORTX Therapeutics, Inc. @XORTXinc]

XORTX Therapeutics Inc. welcomes Abigail Jenkins, a biotech industry veteran with deep experience with the commercialization of therapies for renal and cardiovascular disease, to its Board of Directors.

https://t.co/sPUNC4DmJ1

[XORTX Therapeutics, Inc. @XORTXinc]

Dr. Allen Davidoff, CEO of XORTX Therapeutics Inc, is scheduled to participate in the following Spring 2024 investor and life sciences investment conferences:

- LD Micro Invitational XIV in New York, April 8-9
- Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference, April 17-18
- CEM Scottsdale Capital Event in Scottsdale, April 19-21
- BIO International Convention in San Diego, June 3-6

https://t.co/weB8MK7OgQ

[XORTX Therapeutics, Inc. @XORTXinc]

Dr. Allen Davidoff, CEO of XORTX Therapeutics, shares insights into the company's groundbreaking advancements in therapies for chronic kidney disease and diabetes in an interview with Ellis Martin on Money Talk Radio. #KidneyDisease

https://t.co/VWCe9CCDKR

[XORTX Therapeutics, Inc. @XORTXinc]

Xortx Therapeutics Inc, a Company focusing on treating ADPKD is pleased to welcome Dr. Ronald Perrone to its Clinical Advisory Board. Dr. Perrone, a Professor of Medicine at Tufts University, brings extensive experience in ADPKD clinical trials and research, working closely with regulatory agencies. His expertise will contribute to the Company's advanced clinical program, particularly the XRX-OXY-201 registration trial aimed at slowing #ADPKD progression. #kidneydisease

https://t.co/ekVcQtc5Lf

[XORTX Therapeutics, Inc. @XORTXinc]

XORTX Highlights Achievements of 2023 and Preparations for Registration Clinical Trial

In 2023, substantial progress was made in clinical, technological and regulatory fronts, laying groundwork for 2024 goals. Highlights include US Orphan Drug Designation for XRx-008 in Autosomal Dominant Polycystic Kidney Disease (APDKD) and FDA discussions aligning endpoints for accelerated approval of XORLO™. Collective efforts aim to advance XRx-008 towards registration trials, creating value for XORTX and its stakeholders.

https://t.co/g3Qk2Ad52P

[XORTX Therapeutics, Inc. @XORTXinc]

November is National Diabetes Month, a time when communities across the country seek to bring attention to #diabetes. According to the @CDCgov, approximately 1 in 3 adults with diabetes has #CKD.

Learn more: https://t.co/nsSKqukOza

[XORTX Therapeutics, Inc. @XORTXinc]

Recent research suggests that using multiple diagnostic predictors in combination better predicts patient outcome in autosomal dominant polycystic kidney disease (#ADPKD).

Read the article here: https://t.co/fmUrrjov8k

[XORTX Therapeutics, Inc. @XORTXinc]

Researchers found that the greatest risk factor for sudden cardiac arrest among Hispanic and Latino adults was chronic kidney disease.

Read the @statnews article: https://t.co/NlgDMtiUtT

[XORTX Therapeutics, Inc. @XORTXinc]

Thank you @ASNKidney for hosting a great #KidneyWk conference. Catch up on the $XRTX sponsored study presented last Thursday.

https://t.co/bh0db9nqzo

[XORTX Therapeutics, Inc. @XORTXinc]

Today a $XRTX sponsored study will be presented at the @ASNKidney 2023 #KidneyWK showing decreased uric acid levels, kidney weight and cyst indices in PKD mouse models treated with oxypurinol.

Learn more here: https://t.co/bh0db9nqzo

[XORTX Therapeutics, Inc. @XORTXinc]

Kids with kidney disease can still go trick or treating.

Follow this guide by the National Kidney Foundation (@nkf) here: https://t.co/Qciimq0ZTX

[XORTX Therapeutics, Inc. @XORTXinc]

Most cases of autosomal dominant polycystic disease (#ADPKD) have a family history. However, patients with no apparent family history progress more rapidly to end-stage renal disease.

Read more here: https://t.co/nQ8JSyQneh